Genomics, Inc. (NASDAQ:TXG – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

Cathie Wood's ARK ETFs have made their daily trades public for Wednesday, 29 January 2025, showcasing a series of strategic moves in the tech and biotech sectors. The most significant purchase was in ...

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

These ratings convey expectations for the relative performance of 10x Genomics compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Citigroup lowered their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. Leerink Partnrs upgraded 10x ...

and streamline your search for investment opportunities using Tipranks' Stock Screener Daniel Arias has given his Buy rating due to a combination of factors that highlight 10x Genomics’s strong ...

Stock prices may also move more quickly in this environment. Investors who anticipate trading during these times are strongly advised to use limit orders. Data is delayed at least 15 minutes.

10x Genomics excels in single-cell and spatial ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...